

BioBanking

A212102 NCT05334069		Blinded Reference Set for Multicancer Early Detection Blood Tests
A151804 NCT04242095		Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

Brain

A072201 NCT06325683	Temp. Closed to Accrual 4/13/26	Randomized Phase II Trial of Anti-Lag-3 and Anti-PD-1 Blockade vs. SOC in Patients with Recurrent Glioblastoma
------------------------	---------------------------------------	--

BREAST - Adjuvant HER2+

DFCI 21-159 ATEMPT NCT04893109		A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab vs. Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT 2.0)
A012303 NCT06325683		ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade

BREAST - Adjuvant HER2-

A012301 NCT06671912		A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer (LoTam)
------------------------	--	--

Breast - Adjuvant XRT

CCTG MA.39 NCT03488693		A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
---------------------------	--	---

Metastatic

ASCO CDK Study NCT06377852	Site# JAX-002	08- Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
-------------------------------	------------------	--

Triple Negative

DFCI 18-617 NCT# N/A		A Prospective Registry to Cure Triple-Negative Breast Cancer in Patients With Early-Stage or Newly Diagnosed Metastatic Disease: The TNBC Registry
DFCI 20-166 NCT04468061		Saci-IO TNBC: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC)

Radiation

NRG-BR007 NCT04852887		A Phase III Clinical Trial Evaluating DE-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score \leq 18 Breast Cancer
--------------------------	--	--

Children's Oncology Group Registry

APEC14B1 NCT02402244	Patients 25 years old and younger	Project EveryChild: A Registry, Eligibility Screening, Biology and Outcome Registry
-------------------------	---	---

ComboMATCH Trials

EAY191 NCT05564377		Molecular Analysis for Combination Therapy Choice (ComboMATCH)
EAY191-E5 NCT05638295	Cohort 1 is Temp. Closed to Accrual	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
EAY191-N4 NCT05554328	Ovarian Cohort Closed to Accrual	A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
EAY191-N5 NCT06126276		A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial
EAY191-S3 NCT05554380	Temporarily Closed to Accrual	Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

Colorectal

SWOG S1922 NCT04205968		Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
---------------------------	--	---

Germ Cell

AGCT1531 NCT03067181	Patients <50 years of age	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
AGCT1532 NCT02585697	Patients <=45 years of age	A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

Head and Neck

NRG-HN009 NCT05050162	P16+ OPC/CUP Cohort Closed	Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100mg/m ²) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40mg/m ²) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
--------------------------	-------------------------------	---

Lung Cancer - Adjuvant

A081801 NCT04267848		Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
CTIU2317-A082304-S2402 NCT06632327		Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG

Lung Cancer - 1st Line Metastatic

LUNGMAP NCT03851445		A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
SWOG S1900G NCT05642572		A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
SWOG S1900J NCT06116682		A Phase II Study of Amivantamab in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

SWOG S1900K NCT06031688		A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
SWOG S1800E NCT06616584		A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Lung Cancer - 3B/C and Metastatic

EA5221 NCT06096844		A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
-------------------------------	--	---

Lymphoma

AHOD2131 NCT05675410	Patients <60 years of age	A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
---------------------------------	---	--

MCGI

MCGI 2.0		The Maine Cancer Genomics Initiative (MCGI) 2.0: A Study of Oncology Clinician and Patient Experiences with Clinical Genomics in Northern New England
-----------------	--	---

Prostate

SWOG S1802 NCT03678025		Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
NRG-GU008 NCT04134260		Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

Rare Tumors

TAPUR NCT02693535		The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
------------------------------	--	---

Renal Cell

A032201 NCT06661720		Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (STRIKE)
--------------------------------------	--	---

Urothelial

A032103 NCT05987241		MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant Therapy in Urothelial CaNcer
--------------------------------------	--	--